# An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia

> **NCT05426733** · PHASE3 · ENROLLING_BY_INVITATION · sponsor: **Albireo, an Ipsen Company** · enrollment: 180 (estimated)

## Conditions studied

- Biliary Atresia

## Interventions

- **DRUG:** Odevixibat

## Key facts

- **NCT ID:** NCT05426733
- **Lead sponsor:** Albireo, an Ipsen Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2022-07-05
- **Primary completion:** 2028-08-31
- **Final completion:** 2028-08-31
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05426733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05426733, "An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05426733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*